José Luis Sánchez Carazo *

Autor invitado por SIIC

SEGURIDAD DEL ETANERCEPT EN LA PSORIASIS

El etanercept es un fármaco biológico para el tratamiento de la psoriasis moderada a grave que presenta un perfil de seguridad alto, en el que destaca únicamente la existencia de reacciones locales en el punto de inyección como efecto adverso más frecuente, sin que se haya detectado aumento de tumores o infecciones.

*José Luis Sánchez Carazo
describe para SIIC los aspectos relevantes de su trabajo
SAFETY OF ETANERCEPT IN PSORIASIS: A CRITICAL REVIEW
Institución principal de la investigación
*, Valencia, España, Valencia, España
Imprimir nota

Comprar este artículo
Otros artículos escogidos

Referencias bibliográficas
Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 14:485-496, 1996.
Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents J Am Acad Dermatol 46:1-23, 2002.
Mizutani H, Ohmoto Y, Mizutani T, Murata M, Shimizu M. Role of increased production of monocytes TNF-alpha, IL-1beta and IL-6 in psoriasis:relation to focal infection, disease activity and responses to treatments. J Dermatol Sci 14(2):145-153, 1997.
Mease PJ. Tumor necrosis factor (TNF) in psoriatic arthritis: Pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 61;298-304, 2002.
Chaudhari U, Romano P, Mulcahy D et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357:1842-7, 2001.
Goffe B, Cather JC. Etanercept: an overview. J Am Acad Dermatol 49:S105-11, 2003.
Roberts L , McColl G. J. Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis. Internal Medicine Journal 34:687-693, 2004.
Gottlieb A. Etanercept for the treatment of psoriasis and psoriatic artritis. Dermatolic Therapy 17:401-408, 2004.
Zeltser R, Valle L, Tanck C et al. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha areceptor Fc fusion protein. Arch Dermatol 137(7):893-9, 2001.
Skitta E, Pohjankoski H, Savolainen A. Etanercept and urticaria in patients with juvenile idiopathic arthritis. Clin Exp Rheumatism 18(4):533-4, 2000.
Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schiwieterman Wd et al. Tuberculosis associated with infliximab, a tumor necrosis alpha-neutralizing agent. N Engl J Med 345:1098-1104, 2001.
Klareskog L. Moreland LM, Cohen SB, Sandra M, Burge DJ. Global safety and efficacy of up to five years of Etabercept (Enbrel) therapy [abstract]. Arthritis Rheum 44(suppl):S77, 2001.
Cohen RB. Dittrich KA. Anti-TNF therapy and malignancy: a critical review. Can J Gastroenterol 15:376-84, 2001.
Hofman FM. Hinton DR, Johnson K, et al. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 170:607-12, 1989.
Deswal A, Bozkurt B, Seta Y, et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (enbrel, etanercept) in patients with avanced herat failure. Circulation 99:3224-6, 1999.
Chung ES. Packer M, Lo KH. Randomized, double blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis-a, in patients with moderate-to-severe heart failure: results of theAnti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107:3133, 2003.
Lowell DJ, Gianini EH, Reiff EH et al. Etanercept in children with polyarticular juvenike rheumatoid artritis. N Engl J Med 342(11):763-9.
Peterson JR, Hsu FC, Simkin PA et al. Effect of tumour necrosis factor a antagonists on serum transaminases and viraemia in patients with rheumatoid artritis and chronic hepatitis C infection. Ann Rheum Dis 62:1078-82, 2003.
Allen EJ, Hurley Y, Leonardi C. Etanercept therapy in psoriasis patients with hepatitis C. In American Academy of Dermatology 18-22, 2005; Schaumburg (IL): American Academy of Dermatology 2004.